New minimally invasive technologies for the treatment of pancreatic cancer

A fleet of microscopic, magnetically steered robots will snake through the delicate ducts of the pancreas to deliver cancer drugs directly to tumours. This matters because pancreatic cancer is the deadliest common cancer—95% of patients die within two years, and current treatments are brutal. The pancreas is a fragile, deeply buried organ that surgeons cannot easily reach without causing major damage. Existing therapies, such as chemotherapy, poison the whole body and produce severe side effects. The research aims to replace these blunt tools with a precision approach: soft, millimetre-scale robots that can navigate the pancreas’s intricate internal anatomy without cutting into healthy tissue. If the technology succeeds, it could transform pancreatic cancer from a death sentence into a manageable condition. Patients might receive targeted treatment with few side effects, preserving their quality of life. The same robotic platform could also be adapted for earlier diagnosis, catching tumours before they spread. Beyond this single cancer, the fundamental engineering of magnetically controlled soft robots could open new routes for minimally invasive surgery in other hard-to-reach organs, quietly changing how surgeons treat diseases that currently require major operations.